Is ETAR or JNJ a better dividend investment in 2026?

ETAR currently yields 20000.00% with a 5% 5-year dividend growth rate. JNJ yields 2.14% with 5.8% growth. The better choice depends on your goal: ETAR offers higher current income.

What is the dividend yield difference between ETAR and JNJ?

ETAR has a forward dividend yield of 20000.00% ($2.00/share annually). JNJ yields 2.14% ($5.20/share annually). The yield gap is 19997.86 percentage points.

Home › Compare › ETAR vs JNJ

ETAR vs JNJ: Dividend Comparison 2026

ETAR yields 20000.00% · JNJ yields 2.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ETAR wins by $52481917574412746752.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ETAR

● Live price

20000.00%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$52481917574412746752.00M

Annual income

$51,970,745,957,167,775,000,000,000.00

Full ETAR calculator →

JNJ

Johnson & Johnson

● Live price

2.14%

Share price

$242.49

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.5K

Annual income

$4,749.88

Full JNJ calculator →

Portfolio growth — ETAR vs JNJ

📍 ETAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ETAR	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ETAR + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ETAR pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETAR

Annual income on $10K today (after 15% tax)

$1,700,000.00/yr

After 10yr DRIP, annual income (after tax)

$44,175,134,063,592,610,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$182.28/yr

After 10yr DRIP, annual income (after tax)

$4,037.40/yr

At 15% tax rate, ETAR beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETAR + JNJ for your $10,000?

ETAR: 50%JNJ: 50%

100% JNJ50/50100% ETAR

Portfolio after 10yr

$26240958787206373376.00M

Annual income

$25,985,372,978,583,888,000,000,000.00/yr

Blended yield

99.03%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ETAR

No analyst data

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-5.7% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETAR buys

JNJ buys

No recent congressional trades found for ETAR or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricETARJNJ

Forward yield	20000.00% ✓	2.14%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$52481917574412746752.00M ✓	$30.5K
Annual income after 10y	$51,970,745,957,167,775,000,000,000.00 ✓	$4,749.88
Total dividends collected	$52448189483771600896.00M ✓	$15.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ETAR vs JNJ ($10,000, DRIP)

Year	ETAR Portfolio	ETAR Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$2,010,700	$2,000,000.00	$10,594	$274.49	+$2.00M → ETAR
2	$377,983,225	$375,831,775.70	$11,294	$360.69	+$377.97M → ETAR
3	$66,433,479,469	$66,029,037,418.28	$12,133	$476.91	+$66433.47M → ETAR
4	$10,916,985,471,987	$10,845,901,648,955.73	$13,156	$635.42	+$10916985.46M → ETAR
5	$1,677,384,363,769,318	$1,665,703,189,314,291.80	$14,432	$854.61	+$1677384363.75M → ETAR
6	$240,985,175,079,139,100	$239,190,373,809,905,920.00	$16,056	$1,162.76	+$240985175079.12M → ETAR
7	$32,373,573,631,143,694,000	$32,115,719,493,809,017,000.00	$18,175	$1,604.53	+$32373573631143.68M → ETAR
8	$4,066,766,648,320,630,000,000	$4,032,126,924,535,306,000,000.00	$21,009	$2,252.68	+$4066766648320630.00M → ETAR
9	$477,730,483,406,513,300,000,000	$473,379,043,092,810,300,000,000.00	$24,911	$3,229.73	+$477730483406513344.00M → ETAR
10	$52,481,917,574,412,750,000,000,000	$51,970,745,957,167,775,000,000,000.00	$30,458	$4,749.88	+$52481917574412746752.00M → ETAR

ETAR vs JNJ: Complete Analysis 2026

ETAR — Stock

Entertainment Arts Inc. owns and operates three subsidiaries including JJS Development Inc., I-Zone Inc., and Song Factory Inc. The company's subsidiaries JJS Development offer direct marketing services; I-Zone develops and constructs entertainment and business communication centers and facilities; and Song Factory develops, markets, and distributes karaoke music software products in compact disc (CD) and graphic formats. Entertainment Arts Inc. is based in Orlando, Florida.

Full ETAR Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this ETAR vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETAR vs SCHD ETAR vs JEPI ETAR vs O ETAR vs KO ETAR vs MAIN ETAR vs ABBV ETAR vs MRK ETAR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.